To suppress such abnormal activation of EGFR, EGFR-tyrosine kinase inhibitors (EGFR-TKIs), e. g., gefitinib and erlotinib, have been developed and used as anti-cancer drugs[4–6]. This evidence concerns the gene EGFR and cancer.